Special Issue "Mitochondrial Metabolic Reprogramming and Nuclear Crosstalk in Cancer"
Deadline for manuscript submissions: 30 June 2019
Dr. Benny Abraham Kaipparettu
Though aerobic glycolysis is an established phenomenon in cancer cells, recent developments in cancer metabolism suggest that most tumor mitochondria are not completely dysfunctional, but reprogram to have their ability to carry out oxidative phosphorylation (OXPHOS). Recently, increasing experimental evidence shows a critical role of OXPHOS in tumorigenesis and metastasis. Aggressively metastatic cancer cells, including tumor initiating cancer stem cells can acquire a stable ‘hybrid metabolic phenotype’ with high glycolytic and OXPHOS activity. Hybrid phenotype allows cancer cells to utilize multiple fuels for energy and to maintain a moderate reactive oxygen species (ROS) signalling. Extensive crosstalk between the mitochondria and the nucleus known as mitochondrial retrograde regulation (MRR), also influences many tumor and cellular activities. Importantly, several proto-oncogenes and tumor suppressors are actively involved in the regulation of metabolism. Many of them are known to locate inside the mitochondria but with unknown functional significance. Contrarily, metabolic reprogramming is also known to regulate the activation of oncoproteins by transcriptional and post-translational regulations. Recently, metabolically targeting of cancer cells is gaining increasing attention in oncology. Interestingly, repurposing of established metabolic targets like metformin is now considering for cancer prevention or therapy. Several metabolic targets are also now evaluating for sensitizing cancer cells to radiation and chemotherapy. Considering the heterogeneity of tumors, characterizing mitochondrial reprogramming and MRR in cancer subtypes is critical in understanding the mechanism of tumour initiation, progression and therapeutic resistance. It can also support the development of newer agents to metabolically target cancer subtypes and the repurposing of existing metabolic drugs for cancer therapy.
Dr. Benny Abraham Kaipparettu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cancer metabolism
- Transmitochondrial cybrids
- Metabolic reprogramming
- Mitochondria-nuclear crosstalk
- Hybrid metabolic status
- Reactive oxygen species